AVN 63.71 No Change ▼ 0.00 (0%)
BOP 8.77 No Change ▼ 0.00 (0%)
CHCC 134.55 No Change ▼ 0.00 (0%)
DCL 10.01 No Change ▼ 0.00 (0%)
DGKC 108.01 No Change ▼ 0.00 (0%)
EFERT 64.27 No Change ▼ 0.00 (0%)
EPCL 41.21 No Change ▼ 0.00 (0%)
FCCL 21.00 No Change ▼ 0.00 (0%)
FFL 15.10 No Change ▼ 0.00 (0%)
HASCOL 15.05 No Change ▼ 0.00 (0%)
HBL 130.50 No Change ▼ 0.00 (0%)
HUBC 81.75 No Change ▼ 0.00 (0%)
HUMNL 7.35 No Change ▼ 0.00 (0%)
JSCL 24.29 No Change ▼ 0.00 (0%)
KAPCO 28.49 No Change ▼ 0.00 (0%)
KEL 3.70 No Change ▼ 0.00 (0%)
LOTCHEM 11.71 Decreased By ▼ -0.01 (-0.09%)
MLCF 41.98 No Change ▼ 0.00 (0%)
OGDC 93.20 No Change ▼ 0.00 (0%)
PAEL 32.90 No Change ▼ 0.00 (0%)
PIBTL 12.76 No Change ▼ 0.00 (0%)
PIOC 95.00 No Change ▼ 0.00 (0%)
POWER 9.72 Decreased By ▼ -0.03 (-0.31%)
PPL 83.50 No Change ▼ 0.00 (0%)
PSO 200.02 No Change ▼ 0.00 (0%)
SNGP 56.52 No Change ▼ 0.00 (0%)
STPL 13.15 No Change ▼ 0.00 (0%)
TRG 46.90 No Change ▼ 0.00 (0%)
UNITY 23.05 No Change ▼ 0.00 (0%)
WTL 1.04 No Change ▼ 0.00 (0%)
BR100 4,133 Decreased By ▼ -155.2 (-3.62%)
BR30 21,019 Decreased By ▼ -858.48 (-3.92%)
KSE100 39,888 Decreased By ▼ -1298.86 (-3.15%)
KSE30 16,750 Decreased By ▼ -546.72 (-3.16%)
COVID-19 TOTAL DAILY
Business

US vaccine program head Slaoui expects Pfizer, Moderna vaccine data readouts in Nov-Dec

  • The first wave would be coming from Pfizer and Moderna, both of which are developing mRNA-based vaccines for the coronavirus.
  • At that time, we will have very few doses to be able to, if the decision was to approve the vaccine, immunize.
07 Oct 2020

The chief adviser for the US government's Operation Warp Speed COVID-19 vaccine program, Moncef Slaoui, on Tuesday said efficacy data readouts are expected from Pfizer Inc and Moderna Inc between next month and December.

Speaking at a symposium conducted by the Johns Hopkins University and the University of Washington, Slaoui said data readouts from leading vaccine developers are expected to come in three waves over the next several months.

The first wave would be coming from Pfizer and Moderna, both of which are developing mRNA-based vaccines for the coronavirus, he said.

Slaoui said efficacy data on one or two vaccines will be available within the next month or two, for which there will be enough doses to immunize 30 million people between November and December.

Commenting on AstraZeneca's vaccine program, Slaoui said while the company's US study remains on hold, data readouts on the vaccine's effectiveness may be expected somewhere in late October or November from ongoing studies in the UK, Brazil and South Africa.

"At that time, we will have very few doses to be able to, if the decision was to approve the vaccine, immunize," he said, adding that efforts are in place to scale up manufacturing and stockpiling of the vaccine.